CancerVax Corporation Presents Preclinical Data Demonstrating Tumor Inhibition By D93, A Novel Anti-Angiogenic Monoclonal Antibody
Published: Apr 04, 2006
CancerVax Corporation (NASDAQ: CNVX) announced today that its wholly owned subsidiary, Cell-Matrix, Inc., presented preclinical data indicating that D93, the Company's leading anti-angiogenic and anti-tumorigenic, humanized, monoclonal antibody, inhibited human breast and pancreatic tumor growth in animal models. The presentation, which was made at the 97th Annual Meeting of the American Association for Cancer Research (AACR) in Washington, D.C., on April 2, 2006, also included the results of toxicological and pharmacokinetic studies with D93. On March 1, 2006, the Company announced that it had filed an Investigational New Drug application with the United States Food and Drug Administration for D93.